Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapse/refractory FLT3-mutated acute myeloid leukemia - PubMed
2 hours ago
- #AML
- #HSCT
- #gilteritinib
- Maintenance treatment with gilteritinib after allogeneic hematopoietic stem cell transplantation (HSCT) improves relapse-free survival in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).
- In a Japanese nationwide study, post-HSCT gilteritinib had a median starting dose of 80 mg beginning at day 47 post-transplant, with serious adverse events leading to dose adjustments in 52.7% of patients.
- Patients receiving post-HSCT gilteritinib had a significantly better 3-year relapse-free survival (58.8%) compared to those without it (36.4%), with particular benefit observed in cord blood transplantation (79.4% vs 26.1%).
- The study supports the real-world tolerability and effectiveness of gilteritinib maintenance after HSCT for FLT3-mutated AML, using data from a national registry and a historical cohort.